We previously identified the angiogenesis inhibitor angiostatin. Using a similar strategy, we
have identified endostatin, an angiogenesis inhibitor produced by hemangioendothelioma. …

… Michael OReilly (moreillyjcycor.ca) is a freelance writer living in London, Ont All research for
this article, including interviews, was conducted on line. OReilly says this may mean he is at …

The phenomenon of inhibition of tumor growth by tumor mass has been repeatedly studied,
but without elucidation of a satisfactory mechanism. In our animal model, a primary tumor …

Class I: Conditions for which there is evidence and/or general agreement that a given
procedure or treatment is useful and effective. Class II: Conditions for which there is conflicting …

Acquired drug resistance is a major problem in the treatment of cancer. Of the more than
500,000 annual deaths from cancer in the United States 1 , many follow the development of …

In cancer patients, dormant micrometastases are often asymptomatic and clinically undetectable,
for months or years, until relapse. We have studied dormant lung metastases under …

To reveal the antiangiogenic capability of cancer chemotherapy, we developed an alternative
antiangiogenic schedule for administration of cyclophosphamide. We show here that this …

There is now considerable direct evidence that tumor growth is angiogenesis–dependent 1–4
. The most compelling evidence is based on the discovery of angiostatin, an angiogenesis …

Ischemia often precedes neovascularization. Inocular neovascularization, such as occurs in
diabetic retinopathy, a diffusible angiogenic factor has been postulated to be produced by …

Background: In previous animal studies, interleukin 12 (IL 12) was shown to inhibit the growth
of a wide spectrum of tumors in vivo but to have no direct effect on tumor cells in vitro. Also, …